Muhammad Sheikh, MD
Pulmonary Disease · Memphis, TNNPI 1225317126
Payments from drug & device makers
Across 157 payments — averaging $28.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- Actelion Pharmaceuticals US, Inc.$816
- GSK$434
- AstraZeneca$298
- United Therapeutics Corporation$289
- Novartis$162
- plus $1K from 26 others
What the payments were for
- Travel & lodging$1,02423%
- Food & beverage$3,47577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 2 | $1,024 |
| Actelion Pharmaceuticals US, Inc. | 43 | $816 |
| GSK | 31 | $434 |
| AstraZeneca(2 entities) | 11 | $298 |
| United Therapeutics Corporation | 6 | $289 |
| Novartis | 9 | $162 |
| Genentech USA, Inc. | 3 | $161 |
| Intuitive Surgical | 2 | $152 |
| La Jolla Pharmaceutical Company | 4 | $144 |
| Insmed, Inc. | 6 | $127 |
| Boehringer Ingelheim | 5 | $103 |
| Mylan Specialty L.p. | 4 | $87 |
| Boston Scientific | 1 | $70 |
| Sanofi | 3 | $66 |
| Jazz Pharmaceuticals Inc. | 2 | $58 |
| Mallinckrodt Hospital Products Inc. | 3 | $57 |
| AbbVie | 3 | $53 |
| Portola Pharmaceuticals, LLC | 2 | $47 |
| Gilead | 2 | $44 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $38 |
| Caris MPI, Inc. | 1 | $35 |
| Bayer | 2 | $32 |
| Merck | 2 | $31 |
| Pinnacle Biologics, Inc | 1 | $26 |
| Davol Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sandoz | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pulmonx Endobronchial Valve EBV$1,024
- Da Vinci Surgical System$135
- UPTRAVI$114
- OPSUMIT$114
- TYVASO$103
How this compares
$4,500 in reported general payments places this provider in the 50th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 38 | $893,839 |
| OpsumitMacitentan | 40 | $478,122 |
| AdempasRiociguat | 27 | $365,624 |
| WinrevairSotatercept-Csrk | 11 | $288,120 |
| UptraviSelexipag | 11 | $270,142 |
| OfevNintedanib Esylate | 20 | $242,532 |
| Orenitram ErTreprostinil Diolamine | 12 | $180,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $30,808 |
| Ambrisentan | 11 | $22,279 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $16,970 |
| Tadalafil | 17 | $13,648 |
| EliquisApixaban | 17 | $9,574 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,153 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $8,961 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $816 | $748,26451 claims |
| BayerAdempas | $32 | $365,62427 claims |
| MerckWinrevair | $31 | $288,12011 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $103 | $251,49335 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $434 | $54,08791 claims |
| AstraZenecaSymbicort | $298 | $9,15323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Memphis
- Andrew HoltMemphis$69K
- Jeffrey WrightMemphis$57K
- Patrick HigginsMemphis$49K
- Dipen KadariaMemphis$31K
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.